| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | PI-103 | GDSC1000 | pan-cancer | AAC | 0.11 | 0.0003 |
| mRNA | Cetuximab | GDSC1000 | pan-cancer | AAC | -0.12 | 0.0003 |
| mRNA | OSI-027 | GDSC1000 | pan-cancer | AAC | 0.11 | 0.0004 |
| mRNA | BIX-01294 | CTRPv2 | pan-cancer | AAC | 0.12 | 0.0004 |
| mRNA | ML162 | CTRPv2 | pan-cancer | AAC | 0.12 | 0.0004 |
| mRNA | piperlongumine | CTRPv2 | pan-cancer | AAC | 0.11 | 0.0004 |
| mRNA | 1S,3R-RSL-3 | CTRPv2 | pan-cancer | AAC | 0.12 | 0.0004 |
| mRNA | tretinoin:navitoclax (4:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.13 | 0.0004 |
| mRNA | FQI-1 | CTRPv2 | pan-cancer | AAC | 0.17 | 0.0004 |
| mRNA | PL-DI | CTRPv2 | pan-cancer | AAC | 0.11 | 0.0004 |